An autoantibody reduction regimen that combines three treatments improved lung function and survival in adults with idiopathic pulmonary fibrosis (IPF) who are experiencing acute symptom worsening, a small study suggests. Early, positive clinical responses predicted better long-term outcomes, and high levels of autoantibodies against epithelial markers before treatment were…
AdAlta announced that AD-214, its candidate treatment for idiopathic pulmonary fibrosis (IPF), has been successfully made into an aerosol for inhalation — a nebulized form — while retaining the molecular properties that supported its potential effectiveness in preclinical studies. “The results of these studies support AD-214 being delivered by…
Some people with so-called “long COVID” — breathlessness and other respiratory symptoms that persist long after the acute phase of COVID-19 infection — may have had undiagnosed pulmonary fibrosis before they contracted the infection. Scientists at University of Michigan Health reported these findings in the study, “…
Pulmonary rehabilitation is as effective a treatment for idiopathic pulmonary fibrosis (IPF) as it is for chronic obstructive pulmonary disease (COPD), a real-world study found. “Patients with IPF have similar completion rates and magnitude of response to pulmonary rehabilitation [to patients with COPD],” its scientists wrote. “These data reinforce the…
The levels of a cancer-suppressing molecule called microRNA-326 (miR-326) are reduced significantly in the lungs of a mouse model of silica-induced pulmonary fibrosis (PF), a study shows. Increasing the levels of miR-326 in these mice lessened lung scarring (fibrosis) and suppressed the production of pro-fibrotic molecules, highlighting miR-326 as a…
The first healthy volunteer has been dosed in a trial evaluating ISM001-055, Insilico Medicine’s artificial intelligence (AI)-discovered therapy candidate for idiopathic pulmonary fibrosis (IPF). “We are very pleased to see Insilico Medicine’s first antifibrotic [treatment] candidate entering into the clinic,” Feng Ren, PhD, Insilico’s chief strategy officer, said…
Cudetaxestat (BLD-0409), an investigational therapy for idiopathic pulmonary fibrosis (IPF), showed favorable safety and tolerability in a Phase 1 trial of healthy volunteers. Developed by Blade Therapeutics, cudetaxestat is designed to block the activity of an enzyme called autotaxin that produces a pro-scarring (fibrotic) signaling molecule. This enzyme commonly…
Chiesi announced it has secured from UCB rights to zampilimab, a monoclonal antibody being investigated to treat idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Under the agreement, Chiesi acquired global exclusive rights to develop and manufacture the potential antifibrotic therapy, and to market it should it be approved.
PF Warriors has partnered with online shopping site Joe & Bella to make holiday gift-giving easier for people with pulmonary fibrosis (PF) — while raising funds for the nonprofit’s mission of increasing awareness of PF and other interstitial lung diseases (ILDs). Products sold at Joe & Bella…
NXP002, Nuformix’s experimental inhaled therapy for idiopathic pulmonary fibrosis (IPF), achieves significant levels in the lungs and lowers the production of molecules that promote scarring, according to preclinical studies involving rats, the company announced. “We’re delighted with the positive readout of this data so far and it further…
Get regular updates to your inbox.
